Brief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
06/10/2026 12:53
BRIEF-Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease Oct 6 (Reuters) - SCYNEXIS Inc SCYX.O:
SCYNEXIS ANNOUNCES PHASE 1 STUDY RESULTS FOR SCY-770, A NOVEL, HIGHLY SELECTIVE, ORAL DIRECT AMPK ACTIVATOR FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
SCYNEXIS - SCY-770 WELL TOLERATED WITH FAVORABLE SAFETY PROFILE AT HIGHER DOSES IN PHASE 1 STUDY
SCYNEXIS - PHASE 2 STUDY OF SCY-770 IN ADPKD ON TRACK TO INITIATE IN Q4 2026
Source text: ID:nGNX12KQ9w
Further company coverage: SCYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview